Syngenis One, from target to synthesis ready oligo in one workflow.
Our platform identifies targets, designs candidates, screens for off target effects and orders synthesis, all in one guided workflow.
From target to synthesis ready oligo, in one workflow.
Syngenis One (AI Discovery) is an end to end platform for designing antisense oligonucleotides and aptamers. It unifies work that normally spans half a dozen disconnected tools, target lookup, candidate design, biophysical property calculation, off target screening and synthesis ordering, into a single guided pipeline, so a team moves from a gene of interest to a ranked, orderable candidate list without leaving the browser.
One system, four connected capabilities.
Oligonucleotide properties calculator
Analyse your own oligos, or auto generate ranked antisense candidates against any target, with GC percentage, melting temperature, molecular weight and binding affinity computed for real chemistries including DNA, RNA, 2' O methyl, 2' MOE, 2' fluoro and LNA, with phosphodiester or phosphorothioate backbones and 5' and 3' end modifications.
Discovery pipelines
Guided multi step workflows for oligonucleotides (target lookup, binding site search, candidate evaluation, synthesis order) and for aptamers (target identification, SELEX style library design, candidate generation, ordering). The platform keeps a whole program organised in one place, from first gene to final order.
Sequence aware design intelligence
RNA and DNA hybrid thermodynamics, target accessibility scoring, a machine learned potency ranker, and automated flags for hepatotoxicity motifs, immune stimulatory sequences and synthesis risk patterns, before you commit budget to synthesis.
Live external data
Pulls directly from NCBI, UniProt and PubChem, so designs start from current, authoritative sequence and target data rather than static local copies.
Better decisions, made faster.
- Compresses weeks into minutes. Candidate generation, property prediction and off target screening that once required separate scripts and specialist tools now run in a single pass.
- Fewer dead end syntheses. Built in design flags and potency ranking steer budget toward candidates likely to work, cutting costly synthesise then fail cycles.
- Decisions backed by the literature. Predictions use published nearest neighbour parameters and peer reviewed motif panels, keeping design choices defensible in grant reports and regulatory filings.
- Built for teams. Role based budgeting, a transparent credit ledger, and shared organisation balances let a lab or a whole institution track resource use by team, user and action.
- No infrastructure to manage. Everything runs in the browser against managed compute, so researchers focus on biology, not bioinformatics setup.
Multi modality and aptamers, built in.
Most AI tools focus only on antisense oligonucleotides or siRNA. Syngenis One (AI Discovery) also designs aptamers for both therapeutic and diagnostic use, a capability not offered by any comparable tool. A program can choose the right modality for the biology rather than the tool.
Trials before the trial.
A connected engine places confirmed candidates into simulated in silico clinical trials, drawing on global patient data, pharmacokinetic models and biomarker datasets, so we can reduce the risk of real world failure before a single patient is enrolled. This is especially valuable for the small, rare disease populations that nucleic acid therapies so often target.
No comparable platform in Australia.
Leading global AI discovery platforms focus on small molecules, or keep their tools for internal use only. No other Australian platform combines target identification, multi modality nucleic acid design, off target screening and synthesis ordering for antisense oligonucleotides, siRNA and aptamers in one workflow, connected straight to a working manufacturer.
Common questions.
Who is Syngenis One (AI Discovery) for?
Biotechnology teams, research groups and diagnostics developers who want to move from target to validated, orderable candidate quickly, with synthesis handled in the same system.
What do I receive?
Ranked targets, designed candidates with calculated properties, off target screening results, and a direct route to order synthesis in our laboratories.
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.